Eli Lilly's late-stage pipeline, led by oral obesity and diabetes drug orforglipron, is set to sustain longer-term growth. Phase 3 data for orforglipron is expected to be published later in 2025.

Only 3% of people who took a placebo lost that ... The most common side effects reported in studies were: Orforglipron is in phase III studies to see how well it works in people who are ...

Cantor noted that Eli Lilly's (LLY) orforglipron, which is in Phase 3 testing, “has shown the strongest profile among oral GLP-1s.” Obesity data on GSBR-1290 is expected in Q2. The investment ...

orforglipron is an oral medication. The drug has already turned in positive phase 2 data in obesity and is expected to deliver phase 3 results in diabetes in 2025’s second quarter, Lilly has ...

New data from Novo Nordisk’s phase 3 trial of an oral ... also reported mid-stage results with its oral candidate orforglipron, a non-peptide GLP-1 agonist. The study – published in the ...

In the oral category Novo Nordisk seems to be well ahead, although Lilly is working on a GLP-1 agonist called orforglipron, which according to Adis Insight started phase 3 testing in obesity last ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.